Lifecore Biomedical (NASDAQ:LFCR) Announces Quarterly Earnings Results

Lifecore Biomedical (NASDAQ:LFCR) announced its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05), Zacks reports. The firm had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. Lifecore Biomedical updated its FY 2025 guidance to EPS.

Lifecore Biomedical Stock Down 22.3 %

Shares of Lifecore Biomedical stock opened at $5.29 on Friday. Lifecore Biomedical has a 12-month low of $3.68 and a 12-month high of $7.99. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21. The stock has a 50 day moving average price of $6.17 and a two-hundred day moving average price of $6.24. The stock has a market capitalization of $195.86 million, a P/E ratio of -9.45 and a beta of 0.96.

Analyst Ratings Changes

Separately, Stephens reaffirmed an “equal weight” rating and issued a $6.00 price objective on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

Insider Activity

In other news, CEO Paul Josephs bought 17,000 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the purchase, the chief executive officer now owns 559,717 shares of the company’s stock, valued at $3,212,775.58. This represents a 3.13 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 32.20% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.